Facebook
Twitter
LinkedIn
Forward
Obesity-Related Asthma: Translating the Science into the Clinic
Obesity is associated with increased asthma risk and morbidity. In this module, we will review some of the underlying mechanisms of obese asthma, and the importance of recognizing that this complex phenotype is comprised of different sub-phenotypes and endotypes. We will then examine different approaches for the management of patients with obesity and asthma, including lifestyle changes, medical and surgical weight loss, and novel pharmacological approaches. Finally, we will discuss knowledge gaps and future directions in the field.
This course is an edited and enhanced recording of the ATS 2022 International Conference session with the same name.
Grant Support: This educational module is supported by an independent medical educational grant from Genentech, Inc.
Target Audience
Clinicians (physicians, nurses, fellows, residents), researchers, administrators, and policymakers: anyone involved in the delivery of care and the science of patients with asthma
Learning Objectives
After successfully completing this module, learners will be able to:
- Identity the heterogeneity of obese asthma, including subphenotypes and endotypes related to atopy, systemic inflammation, and metabolic dysregulation; and describe their impact on asthma management
- Describe and highlight the importance of lifestyle modifications, medical, and surgical weight loss in the management of patients with asthma and obesity
- Discuss new developments in the management of obesity-related asthma and gaps in knowledge to be addressed by ongoing and future research
| Name | Title | Institution | Role | Relationship |
| Anne E. Dixon, MA, BM BCh, ATSF | Professor of Medicine | University of Vermont Larner College of Medicine | Chair; Presenter | MitoQ: Research - investigator initiated NIH: Advisory Committee - non-promotional ABIM: Advisory Committee - non-promotional |
| Jun Ma, MD, PhD | Professor of Medicine | University of Illinois at Chicago, School of Public Health | Presenter | None |
| Erick Forno, MD | Associate Professor of Pediatrics | Children's Hospital Pittsburgh | Chair; Presenter | None |
| Deepa Rastogi, MBBS | Associate Director of Clinical and Translational Science | Children's National Health System | Presenter | None |
| Katherine Cahill, MD | Medical Director of Clinical Asthma Research | Vanderbilt University Medical Center | Presenter | Novartis: Advisory Committee for non-promotional Third Harmonic: Consultant Blueprint Medicines: Advisory Committee for non-promotional GlaxoSmithKline: Advisory Committee for non-promotional Sanofi: Advisory Committee for non-promotional Sanofi Pasteur: Advisory Committee for non-promotional Genentech: Advisory Committee for non-promotional Ribon Therapeutics: Consultant Verantos: Consultant AstraZeneca: Advisory Committee for non-promotional Novo Nordisk: Research - investigator initiated |
| Fernando Holguin, MD | Professor of Pulmonary Medicine | University of Colorado Health Systems | Presenter | Insmed: Advisory Committee for non-promotional FDA: Advisory Committee for non-promotional |
Accreditation Statement
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Disclosure Declaration
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.
This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions to Receive Credit
To earn credit for this course, follow these instructions:
- Launch and complete all modules by viewing every page in the module.
- After you complete the module(s), the post test will become available. You must pass the post these with a 70% score or better.
- Complete the Course Evaluation.
- Once you complete the modules, pass the post test and complete the evaluation, the system will grant you credit.
- To view your transcript and print your certificate, go to the My Account drop-down list. Then select Transcript.
Available Credit
- 1.50 AMA PRA Category 1 Credit(s)™The American Thoracic Society designates this for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Participation